Bioatla Inc.

Bioatla Inc.

Market Cap (Mar-08-2026)
0.01 Billion USD
World Rank (Jan-05-2024)
20,627
Market Cap (Jan-05-2024)
0.117 Billion USD
World Rank (Jul-30-2023)
19,974
Market Cap (Jul-30-2023)
0.138 Billion USD
World Rank (Jan-07-2022)
12,389
Market Cap (Jan-07-2022)
0.594 Billion USD
World Rank (Jan-01-2021)
7,400
Market Cap (Jan-01-2021)
1.145 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
BCAB
Employee Count
36
Employee Count as of Date
As on 2019
Headquarters City/State
California
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Net Income in USD
-95 Million USD
Annual Results for Period Ending
Dec-2021 ending year
Total Assets in USD
254 Million USD
Total Liabilities in USD
43 Million USD
Total Equity in USD
210 Million USD
Balance Sheet for Period Ending
Dec-2021 ending year
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
BIOATLA, INC.
Company Profile
BioAtla is a San Diego Based Biopharmaceutical company that develops novel monoclonal antibody and cell based therapeutics using proprietary Conditionally Active Biologics(CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms. The company annual revenue is 5.20 million USD and 36 employees as on 2019. The headquarters is in USA.
IPO Year
2020
Stock Exchange
Nasdaq
Nasdaq Sector
Health Care
Nasdaq Industry
Medicinal Chemicals and Botanical Products

Share